Prosecution Insights
Last updated: July 17, 2026
Application No. 18/836,191

WATER-SOLUBLE HETEROCYCLYL POLYMETHINE CHROMOPHORES

Non-Final OA §102§112
Filed
Aug 06, 2024
Priority
Feb 07, 2022 — provisional 63/307,509 +2 more
Examiner
JACKSON, SHAWQUIA
Art Unit
1629
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Regents of the University of California
OA Round
1 (Non-Final)
78%
Grant Probability
Favorable
1-2
OA Rounds
4m
Est. Remaining
75%
With Interview

Examiner Intelligence

Grants 78% — above average
78%
Career Allowance Rate
1419 granted / 1820 resolved
+18.0% vs TC avg
Minimal -3% lift
Without
With
+-3.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
45 currently pending
Career history
1851
Total Applications
across all art units

Statute-Specific Performance

§101
1.8%
-38.2% vs TC avg
§103
12.3%
-27.7% vs TC avg
§102
11.0%
-29.0% vs TC avg
§112
62.6%
+22.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1820 resolved cases

Office Action

§102 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claims 1, 2, 5-7, 9, 12, 21, 27, 30, 33, 34, 36, 37, 39, 40, 42-45 are currently pending in the instant application. Applicants have amended claims 1, 2, 5-7, 9, 12, 21, 27, 30, 33, 36, 37, 39, 40, 42-45 and canceled claims 3-4, 8, 10-11, 13-20, 22-26, 28-29, 31-32,35, 38, 41 and 46-50 in amendment filed on August 6, 2024. Claims 1, 43 and 44 are rejected and claims 2, 5-7, 9, 12, 21, 27, 30, 33, 34, 36, 37, 39, 40, 42 and 45 are objected in this Office Action. I. Priority The instant application is a 371 of PCT/US2023/062095, filed on February 7, 2023 which claims benefit of US Provisional Applications 63/402,166, filed on August 30, 2022 and 63/307,509, filed on February 7, 2022. II. Information Disclosure Statement The information disclosure statements (IDS) submitted on August 6, 2024, August 29, 2024, March 21, 2025 and November 26, 2025 are in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statements have been considered by the examiner. III. Rejections Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless - (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1 and 43 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Ohashi, et al. (US 20120119171 A1). The instant invention claims PNG media_image1.png 797 811 media_image1.png Greyscale PNG media_image2.png 130 779 media_image2.png Greyscale The Ohashi, et al. reference teaches the compound PNG media_image3.png 148 368 media_image3.png Greyscale (See page 9, second to last compound on right) wherein A and B are a tricyclic hetaryl ring substituted with butyl on the nitrogen atom and dimethyl at the 3-position; R1 and R2 form a cyclohexenyl ring and all other variables are hydrogen. This species of compound anticipates the genus compound of the instant invention, wherein the genus structure and its definitions are stated above. Claims 1 and 43 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Yamada, et al. (US 2020/0363576 A1). The instant invention claims PNG media_image1.png 797 811 media_image1.png Greyscale PNG media_image2.png 130 779 media_image2.png Greyscale The Yamada, et al. reference teaches the compound PNG media_image4.png 188 420 media_image4.png Greyscale (See page 25, paragraph 0269) wherein A and B are a bicyclic hetaryl ring substituted with ethyl on the nitrogen atom; R1 and R2 form a cyclohexenyl ring and all other variables are hydrogen. This species of compound anticipates the genus compound of the instant invention, wherein the genus structure and its definitions are stated above. Claim Rejections - 35 USC § 112 The following is a quotation of the second paragraph of 35 U.S.C. 112: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 44 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 44 contains the limitation “A method of delivering a compound or composition of claim 1”. However, claim 1 is only drawn to “a compound” and not a “composition” so it is unclear what composition Applicants are referring to in this limitation. This limitation lacks antecedent basis. Applicants are suggested to delete the phrases “or a composition” in claim 44 to overcome the rejection. IV. Objections Dependent Claim Objections Dependent Claims 2, 5-7, 9, 12, 21, 27, 30, 33, 34, 36, 37, 39, 40, 42, 44 and 45 are also objected to as being dependent upon a rejected based claim. To overcome this objection, Applicant should rewrite said claims in an independent form and include the limitations of the base claim and any intervening claim. V. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shawquia Jackson whose telephone number is 571-272-9043. The examiner can normally be reached on 7:00 AM-3:30PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Adam Milligan can be reached on 571-270-7674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). /SHAWQUIA JACKSON/ Primary Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Aug 06, 2024
Application Filed
Apr 22, 2026
Response after Non-Final Action
Jun 11, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12668571
SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28
3y 4m to grant Granted Jun 30, 2026
Patent 12662458
SOLID FORMS OF A COMPOUND
3y 0m to grant Granted Jun 23, 2026
Patent 12655117
PREPARATION OF SUBSTITUTED AROMATIC CARBOXAMIDES
4y 0m to grant Granted Jun 16, 2026
Patent 12655126
IMIDAZOLE-PYRAZOLE DERIVATIVES AS ANTIBACTERIALS
3y 3m to grant Granted Jun 16, 2026
Patent 12655140
Compound containing structure of a heteroaromatic ring, pharmaceutical composition thereof and application thereof
2y 9m to grant Granted Jun 16, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
78%
Grant Probability
75%
With Interview (-3.4%)
2y 3m (~4m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1820 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month